Adrian W. Bott, Ph.D.
Adrian joined the BASi® bioanalysis group in 2006. After 1 year as an analyst, he moved to project management, and has been responsible for multiple method development, method validation, and sample analysis projects, both pre-clinical and clinical. He received a B.A. in Natural Sciences (1986) and a Ph.D. in Chemistry (1989) from the University of Cambridge (UK). Prior to joining the bioanalysis group, Dr. Bott worked for the BASi® electrochemistry group for 15 years following a post-doctoral appointment at Purdue University.
Orlando Bravo , Ph.D.
Orlando joined BASi® in April 2005. He received a PhD. in Organic Chemistry from Texas A&M University and a BS from University of Costa Rica. In his nearly 10 years of experience at BASi® he has extensively worked with method development, method validation, clinical and non-clinical bioanalysis. Dr. Bravo has ample experience with LC-MS/MS, UPLC-CAD and LC-fluorescence methods. He has been involved with numerous client audits and inspections. Dr. Bravo has also been involved with FDA inspections.
Robert Clegg, B.S.
Robert joined BASi in 2011 after receiving a B.S. in Chemistry (ACS accredited) degree from Purdue University. He spent four years as an analyst with both the bioanalytical analysis and method development/method validation teams before transitioning into a project management role. Robert’s responsibilities include the development and validation of bioanalytical assays, client communications, maintaining deadlines, and issuing reports.
R. Tyler Degraw , Ph.D.
Scientific Team Manager
Tyler joined BASi® in 2006. Previously Dr. DeGraw worked for the Pharmaceutical Division of 3M as a Senior Biochemical Pharmacologist. He received his Bachelor of Science in Chemistry degree from Utah State University and aPh.D. in Pharmaceutical Sciences from the University of Kentucky. Dr. DeGraw originally joined BASi® to work with the BASi Culex ® automated blood sampling system, and served as the principal investigator for an NIH grant to transfer the BASi Culex ® technology to large animals. Dr. DeGraw is currently a Scientific Team Manager for the Bioanalytical department where his current responsibilities include coordinating, organizing and scheduling projects with personnel and instrumentation. He also continues to work directly with clients in pharmacokinetic analysis and as a principal investigator on bioanalytical projects. He is a member of the American Association of Pharmaceutical Scientists
Scott joined BASi® in 1988 after earning the ACS Certified B.S. in Chemistry from Purdue University. He has extensive experience in instrumental bioanalysis encompassing HPLC with electrochemical and mass spectrometry methods of detection. His areas of expertise include the development and troubleshooting of analytical methods for pharmaceuticals in numerous matrices and implementation of those methods for rapid, high throughput sample analysis. Current responsibilities include clinical and non-clinical bioanalytical sample analysis project management, sponsor communication, data management and report preparation.
James Hill, Ph.D.
Principal Investigator – Electrochemistry
James joined BASi in February 2016. He completed postdoctoral training at the Missouri University of Science and Technology in 2015, obtained a Ph.D. in Inorganic Chemistry from Purdue University in 2012, and obtained a B.S in Biochemistry from Grove City College in 2006. Dr. Hill currently conducts electrochemistry research and development and offers technical support for electrochemistry and liquid chromatography products at BASi. He has eight publications in peer-reviewed journals and is a member of The Electrochemistry Society, the Society of Electroanalytical Chemistry, and the American Chemical Society.
Srini Jayaraman, Ph.D.
Principal Investigator, In Vivo Discovery Services
Srini joined BASi® in Feb 2015. Dr. Jayaraman is an in vivo pharmacologist, Neurochemist and a neuroscientist with more than 10 years of experience from Pharmaceutical companies and Academia. Prior to joining BASi®, Dr. Jayaraman worked for Schering Plough and Merck as senior and Associate Principal Scientist in the UK and US. He received his Ph.D in Neuroscience from the University of Tuebingen, Max-Planck Research School, Germany in 2004 and completed his postdoctoral training from the University of Bath, England in 2007. Dr. Jayaraman received his undergraduate and postgraduate degrees in Pharmacy and Pharmacology from MGR Medical University, India in 2000. Dr. Jayaraman is currently a Principal Investigator at BASi’s discovery lab and oversees in vivo operations using state-of-the-art BASi Culex ® systems for PK and microdialysis studies. He also extends scientific and technical support to BASi’s clients in the field of Microdialysis, Ultrafiltration and in vivo sampling.
Hasantha Jayaratna, Ph.D.
Hasantha first joined BASi® in 1993 as a post-doctoral scientist in electrochemical division where he conducted governmental grant supported research geared towards instrument development for mass screening of children for blood lead contamination. He later joined as a senior scientist in Method Development division of BASi® CRO in 2005. Dr. Jayaratna has developed and validated numerous bioanalytical LC/MS methods since then and continues with an extensive knowledge of various issues with biological sample analysis and project management.
Steven Kaverman, M.S.
Steven joined BASi in January of 2013. He worked primarily as an analyst in the bioanalytical division working on validations and sample analysis. During his time as an analyst, Steven gained experience with LC-MS/MS, UPLC-CAD, and LC-fluorescence methods. He also worked on several bioequivalence studies in the pharmaceutical analysis department. Steven spent 2.5 years as an analyst before transitioning into a project management role. He received a B.S. in Pharmaceutical Sciences (2007) from Purdue University along with minors in biology and chemistry. He also received a M.S. in Chemical Education (2012) from Purdue University.
Dianne Lim, M.S.
Dianne joined the Pharmaceutical Analysis group at BASi in 2014. She oversees a wide variety of projects, a majority of which involves an emphasis on method development, method validation and sample analysis in support of IND submissions. Dianne has an extensive background in project management and analytical chemistry gained from over 9 years of experience in the environmental laboratory industry. Prior to joining BASi, she managed the Inorganics department at an environmental laboratory engaged in the measurement and regulation of pollutants and byproducts present in drinking water, wastewater, soils and hazardous waste. She received a B.S. and M.S. in Chemistry from California State University, Fresno and is a member of the American Chemical Society (ACS) and American Association of Pharmaceutical Scientists (AAPS).
Rachel Sun , Ph.D.
Assistant Director, Discovery PK/PD
Rachel joined BASi® in 2002. She has more than 14 years of experience in pharmaceutical industry in drug development and contract service. She has developed hundreds of bioanalytical assays to support pre-clinical and clinical studies of different chemical identities including small molecules, peptides and oligonucleotides. Before joining BASi®, Dr. Sun worked as scientist in Barr Laboratories (now Teva Pharmaceutical) and V.I.Technologies. She received a Ph.D. in Chemistry from New York University and a B.S. in chemistry from Peking University, China. Dr. Sun has numerous presentations at professional meetings, such as AAPS and ASMS..
Ellen Wu, Ph.D.
Ellen joined BASi® in 2014. She received her Ph.D. in analytical chemistry from University of Florida, with interdisciplinary research background in cancer diagnosis and targeted cancer therapy. Dr. Wu has authored or coauthored 23 high-caliber peer-reviewed publications and one patent. She was previously Senior Analytical Chemist (method developer, study director and global analytical champion associate) for Syngenta (formerly Novartis Ag.) and Senior Scientist for Becton, Dickinson and Company (BD) focusing on new antibody conjugates development and commercialization and new bioprocess development.